Laboratory for Nanoengineered Materials & Biosensing Technologies

Home » Lab Manager » Members » Anandi Chowdhury

Anandi Chowdhury

CURRENT PEOPLE

Lab Manager

PhD Students

Pragya Swami

Meenakshi Singh1

Rukmini Sarma2

Urvashi Singh

Anandi Chowdhury3

Tejal Dube

Jasmeen Kaur4

 

Co-supervisors:
1Prof. Gaurav Goel, IITD
2Prof. Ravi Elangovan, IITD
3Prof. Ashok Kumar, IITK
4Prof. Rohit Srivastava, IITB

M.Tech. Students

B.TECH students

Project interns

Our Collaborators

anandi.chowdhury@chemical.iitd.ac.in

LinkedIN: https://www.linkedin.com/in/anandic/

Twitter: https://twitter.com/ACinMedicine

Have you ever dreamed of a world with no cancer? I have, every single day since I decided to be a scientist. To start on this journey, I received my B.Tech. and M.Tech. in Biotechnology from Kalinga Institute of Industrial Technology, Bhubaneswar, India. During this time, I gained research experience in infection biology, immunology and cancer therapy from the Calcutta School of Tropical Medicine (Kolkata, India), Bose Institute1 (Kolkata, India) and my university. Additionally, I was awarded DAAD Scholarship in 2018 to represent India and undergo training at Prof. Emmanuelle Charpentier’s (winner of the Nobel Prize in Chemistry 2020) lab at the Max Planck Institute for Infection Biology, Berlin, Germany, on CRISPR-Cas Systems. After completing my degree, I joined Prof. Dhirendra S. Katti’s group as a Junior Research Fellow at the Indian Institute of Technology, Kanpur, India, to develop a non-invasive drug delivery system for diabetic retinopathy.

In order to gain expertise in drug delivery and bioengineering, I joined Prof. Shalini Gupta’s group at the Dept. of Chemical Engineering, Indian Institute of Technology Delhi in 2020 for my Ph.D. Here, my research focuses on studying infections in cancer and finding therapeutic interventions to co-eliminate cancer and bacterial cells simultaneously. The primary goal of my research is to develop a drug delivery system (DDS) to target infections in the tumor microenvironment. Finally, to check the efficacy of the DDS, I plan to screen it on organoid and murine cancer models with the help of Prof. Ashok Kumar (IIT Kanpur, India). The in-vitro and in-vivo studies will help us acquire a more holistic view of the drug’s mechanism of action in eradicating infections and suppressing tumor cells.

References:

1.         Pati S, Chowdhury A, Mukherjee S, Guin A, Mukherjee S, Sa G. Regulatory lymphocytes: the dice that resolve the tumor endgame. Appl Cancer Res. 2020;40(1):7. doi:10.1186/s41241-020-00091-0